Bio-Techne Corporation TECH
Healthcare · Biotechnology · United States · S&P 500
Based on the available data, Bio-Techne Corporation gets an algorithmic score of 58/100. It trades at 72.38 $, with a bullish technical trend (RSI 56.0) and 45.4% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
- Meaningful dividend (44.00%).
Weaknesses
- —
Fundamentals
| P/E | 62.40 |
| Forward P/E | 31.30 |
| PEG | 2.11 |
| P/B | 5.36 |
| EV/EBITDA | 34.04 |
| P/S | 9.34 |
| ROE % | 9.03 |
| ROA % | 6.67 |
| Gross margin % | 66.24 |
| Operating margin % | 27.87 |
| Net margin % | 14.97 |
| Revenue growth % (y/y) | 1.30 |
| Revenue CAGR % | 2.25 |
| Earnings CAGR % | -13.93 |
| Debt/Equity % | 13.71 |
| Current ratio | 4.55 |
| FCF yield % | 2.32 |
| Dividend yield % | 44.00 |
| Payout % | 27.59 |
Returns
| 1 month | +0.0 % |
| 3 months | +2.6 % |
| 6 months | +39.5 % |
| YTD | +21.9 % |
| 1 year | +40.4 % |
| 3 years | +6.0 % |
| 5 years | -44.1 % |
Risk
| 1-year volatility | 45.4 % |
| Beta | 1.11 |
| 5-year max drawdown | -67.2 % |
| Sharpe 1A | 0.88 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.